Jill Durocher

Mifepristone label laws and trends in use: recent experiences in four US states

November 5th, 2015
Staff Publication
Winikoff, Beverly, Sheldon, Wendy R.

Since mifepristone was approved in 2000, the rate of medical abortions has risen fairly steadily from just 6% of all eligible abortions in 2001 to 29% in 2011. If unconstrained access to medical abortions were the norm, rather than the exception, medical abortions might constitute a higher percentage of all abortions. Furthermore, the on-label use of mifepristone involves use of an outdated regimen of 600 mg that is more expensive and arguably less effective, with greater side effects than the evidence-based regimen of 200 mg that is currently the world-wide standard of care. In order to examine further the possible effect of mifepristone-specific restrictions, researchers documented trends in mifepristone use over a 10-year period (2004–2014) in four large US states: California, New York, Ohio and Texas.

Access the article.